Predicts risk of VTE for cancer patients depending on type of cancer and other factors.
The Khorana Risk Score stratifies risk well. In outpatients, VTE risk remains relatively low (~10%) even in the highest score groups.
At least one author group has applied a binary version of the Khorana Risk Score in practice, using the result for clinical decision making.
The Khorana Risk Score requires multiple laboratory variables, and it may not stratify as consistently or accurately in higher risk patients and those with cancers not indicated in the score.